Effect of smoking in a controlled study of ranitidine treatment in gastroesophageal reflux disease

GERD Study Group

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Smoking has been shown to be a factor in acid peptic disease. A recent U.S. multicenter trial investigating use of ranitidine in the treatment of gastroesophageal reflux disease provided an opportunity to compare smokers and nonsmokers with regard to demographic features, manifestations of disease, and symptomatic response to treatment. A comparison of characteristics of smokers and nonsmokers revealed similar pretrial clinical findings. No significant differences between groups were found with regard to previous complications or recent symptoms of gastroesophageal reflux disease. There were also no significant differences in the way smokers and nonsmokers responded to treatment. Subjects on ranitidine, regardless of their smoking status, showed significantly greater improvement in heartburn symptoms and consumed less antacid than subjects who received placebo. Results of these analyses indicate that smoking as an independent variable was not related to symptomatic response or esophageal healing and that ranitidine was similarly effective in decreasing heartburn symptoms in smokers and nonsmokers.

Original languageEnglish (US)
Pages (from-to)499-503
Number of pages5
JournalJournal of Clinical Gastroenterology
Volume9
Issue number5
StatePublished - 1987
Externally publishedYes

Fingerprint

Ranitidine
Gastroesophageal Reflux
Heartburn
Smoking
Antacids
Multicenter Studies
Digestion
Therapeutics
Placebos
Demography
Acids

Keywords

  • Gastroesophageal reflux
  • Ranitidine
  • Smoking

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of smoking in a controlled study of ranitidine treatment in gastroesophageal reflux disease. / GERD Study Group.

In: Journal of Clinical Gastroenterology, Vol. 9, No. 5, 1987, p. 499-503.

Research output: Contribution to journalArticle

@article{dd69ab640d714c868c011b920df72291,
title = "Effect of smoking in a controlled study of ranitidine treatment in gastroesophageal reflux disease",
abstract = "Smoking has been shown to be a factor in acid peptic disease. A recent U.S. multicenter trial investigating use of ranitidine in the treatment of gastroesophageal reflux disease provided an opportunity to compare smokers and nonsmokers with regard to demographic features, manifestations of disease, and symptomatic response to treatment. A comparison of characteristics of smokers and nonsmokers revealed similar pretrial clinical findings. No significant differences between groups were found with regard to previous complications or recent symptoms of gastroesophageal reflux disease. There were also no significant differences in the way smokers and nonsmokers responded to treatment. Subjects on ranitidine, regardless of their smoking status, showed significantly greater improvement in heartburn symptoms and consumed less antacid than subjects who received placebo. Results of these analyses indicate that smoking as an independent variable was not related to symptomatic response or esophageal healing and that ranitidine was similarly effective in decreasing heartburn symptoms in smokers and nonsmokers.",
keywords = "Gastroesophageal reflux, Ranitidine, Smoking",
author = "{GERD Study Group} and Berenson, {Malcolm M.} and Stephen Sontag and Robinson, {Malcolm G.} and McCallum, {Richard M.} and James Achord and Jose Behar and Walter Brooks and Steven Brozinsky and Cunningham, {John T} and Mark Efrusy and Robert Fisher and Joel Levine and William Orr and Fred Thomas and Alvin Zfass and Todd Zimmerman",
year = "1987",
language = "English (US)",
volume = "9",
pages = "499--503",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effect of smoking in a controlled study of ranitidine treatment in gastroesophageal reflux disease

AU - GERD Study Group

AU - Berenson, Malcolm M.

AU - Sontag, Stephen

AU - Robinson, Malcolm G.

AU - McCallum, Richard M.

AU - Achord, James

AU - Behar, Jose

AU - Brooks, Walter

AU - Brozinsky, Steven

AU - Cunningham, John T

AU - Efrusy, Mark

AU - Fisher, Robert

AU - Levine, Joel

AU - Orr, William

AU - Thomas, Fred

AU - Zfass, Alvin

AU - Zimmerman, Todd

PY - 1987

Y1 - 1987

N2 - Smoking has been shown to be a factor in acid peptic disease. A recent U.S. multicenter trial investigating use of ranitidine in the treatment of gastroesophageal reflux disease provided an opportunity to compare smokers and nonsmokers with regard to demographic features, manifestations of disease, and symptomatic response to treatment. A comparison of characteristics of smokers and nonsmokers revealed similar pretrial clinical findings. No significant differences between groups were found with regard to previous complications or recent symptoms of gastroesophageal reflux disease. There were also no significant differences in the way smokers and nonsmokers responded to treatment. Subjects on ranitidine, regardless of their smoking status, showed significantly greater improvement in heartburn symptoms and consumed less antacid than subjects who received placebo. Results of these analyses indicate that smoking as an independent variable was not related to symptomatic response or esophageal healing and that ranitidine was similarly effective in decreasing heartburn symptoms in smokers and nonsmokers.

AB - Smoking has been shown to be a factor in acid peptic disease. A recent U.S. multicenter trial investigating use of ranitidine in the treatment of gastroesophageal reflux disease provided an opportunity to compare smokers and nonsmokers with regard to demographic features, manifestations of disease, and symptomatic response to treatment. A comparison of characteristics of smokers and nonsmokers revealed similar pretrial clinical findings. No significant differences between groups were found with regard to previous complications or recent symptoms of gastroesophageal reflux disease. There were also no significant differences in the way smokers and nonsmokers responded to treatment. Subjects on ranitidine, regardless of their smoking status, showed significantly greater improvement in heartburn symptoms and consumed less antacid than subjects who received placebo. Results of these analyses indicate that smoking as an independent variable was not related to symptomatic response or esophageal healing and that ranitidine was similarly effective in decreasing heartburn symptoms in smokers and nonsmokers.

KW - Gastroesophageal reflux

KW - Ranitidine

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=0023242639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023242639&partnerID=8YFLogxK

M3 - Article

C2 - 3316371

AN - SCOPUS:0023242639

VL - 9

SP - 499

EP - 503

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 5

ER -